186 related articles for article (PubMed ID: 25557847)
1. Elevation of serum KL-6 in patients with psoriasis treated with anti-tumour necrosis factor-α therapy.
Higashi Y; Tada K; Shimokawa M; Kawai K; Kanekura T
Clin Exp Dermatol; 2016 Jan; 41(1):88-90. PubMed ID: 25557847
[TBL] [Abstract][Full Text] [Related]
2. Secukinumab decreases serum Krebs von den Lungen 6 (KL-6) level in patients with psoriasis with elevated serum KL-6 level.
Chijiwa C; Takeoka S; Kamata M; Uchida H; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
Br J Dermatol; 2018 Dec; 179(6):1396-1397. PubMed ID: 29985537
[No Abstract] [Full Text] [Related]
3. Impact of anti-tumor necrosis factor-α agents on serum levels of KL-6 and surfactant protein-D in patients with psoriasis.
Hayashi M; Yanaba K; Umezawa Y; Asahina A; Nakagawa H
J Dermatol; 2017 Sep; 44(9):1063-1066. PubMed ID: 28370220
[TBL] [Abstract][Full Text] [Related]
4. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C.
Ishikawa T; Kubota T; Abe H; Hirose K; Nagashima A; Togashi T; Seki K; Honma T; Yoshida T; Kamimura T
Hepatogastroenterology; 2012 Oct; 59(119):2260-3. PubMed ID: 23435141
[TBL] [Abstract][Full Text] [Related]
5. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs.
Harigai M; Takamura A; Atsumi T; Dohi M; Hirata S; Kameda H; Nagasawa H; Seto Y; Koike T; Miyasaka N
Mod Rheumatol; 2013 Mar; 23(2):284-96. PubMed ID: 22588312
[TBL] [Abstract][Full Text] [Related]
6. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
Kuwana M; Shirai Y; Takeuchi T
J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
[TBL] [Abstract][Full Text] [Related]
7. Early detection of colon cancer by increased serum level of Krebs von den Lungen-6 in a patient with dermatomyositis-associated interstitial pneumonia.
Fukuhara N; Tanino Y; Sato S; Fukuhara A; Uematsu M; Nikaido T; Misa K; Sato Y; Saito J; Wang X; Munakata M
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):265-70. PubMed ID: 26422573
[TBL] [Abstract][Full Text] [Related]
8. Elevation of serum KL-6 levels during treatment with tumor necrosis factor-α inhibitor in patients with psoriasis.
Mabuchi T; Yamaoka H; Kawai M; Ota T; Ozawa A
J Dermatol; 2014 Dec; 41(12):1136-7. PubMed ID: 25388751
[No Abstract] [Full Text] [Related]
9. Potential of Krebs von den Lungen-6 as a predictor of relapse in interstitial pneumonia with anti-aminoacyl tRNA synthetase antibodies-positive dermatomyositis.
Isoda K; Kotani T; Takeuchi T; Konma J; Ishida T; Hata K; Otani K; Fujiwara H; Shoda T; Makino S; Arawaka S
Clin Respir J; 2018 Jul; 12(7):2235-2241. PubMed ID: 29633527
[TBL] [Abstract][Full Text] [Related]
10. Serum KL-6 levels in Japanese patients with psoriasis treated with secukinumab.
Kurita M; Kikuchi S; Umezawa Y; Asahina A; Nakagawa H; Yanaba K
J Dermatol; 2019 Apr; 46(4):e115-e116. PubMed ID: 30204267
[No Abstract] [Full Text] [Related]
11. Effect of anti-interleukin-17 biologics on Krebs von den Lungen-6 level in patients with psoriasis.
Hara H; Miyagawa H; Araya J; Minagawa S; Numata T; Umezawa Y; Asahina A; Nakagawa H; Kuwano K
J Dermatol; 2021 Jun; 48(6):886-893. PubMed ID: 33860559
[TBL] [Abstract][Full Text] [Related]
12. Serum Krebs von den Lungen-6 levels in psoriatic patients under treatment with biologics.
Iwata H; Haga N; Sugai T; Fujita Y
J Dermatol; 2021 Mar; 48(3):376-379. PubMed ID: 33146900
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease.
Takanashi S; Nishina N; Nakazawa M; Kaneko Y; Takeuchi T
Rheumatology (Oxford); 2019 Jun; 58(6):1034-1039. PubMed ID: 30624752
[TBL] [Abstract][Full Text] [Related]
14. Change in Serum KL-6 Level during Biologic Treatment for Psoriasis.
Hoashi T; Miyazaki S; Ozaki S; Ichiyama S; Ito M; Kanda N; Saeki H
J Nippon Med Sch; 2023; 90(2):194-201. PubMed ID: 37258257
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
Gisondi P; Cotena C; Tessari G; Girolomoni G
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
[TBL] [Abstract][Full Text] [Related]
16. The Value of Biomarkers as Predictors of Outcome in Patients with Rheumatoid Arthritis-Associated Usual Interstitial Pneumonia.
Lee YS; Kim HC; Lee BY; Lee CK; Kim MY; Jang SJ; Lee HS; Moon J; Colby TV; Kim DS
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Oct; 33(3):216-223. PubMed ID: 27758986
[TBL] [Abstract][Full Text] [Related]
17. Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease.
Qin H; Xu XP; Zou J; Zhao XJ; Wu HW; Zha QF; Chen S; Kang Y; Jiang HD
Pulmonology; 2019; 25(3):143-148. PubMed ID: 30007895
[TBL] [Abstract][Full Text] [Related]
18. Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases.
Cho EJ; Park KJ; Ko DH; Koo HJ; Lee SM; Song JW; Lee W; Lee HK; Do KH; Chun S; Min WK
Ann Lab Med; 2019 May; 39(3):245-251. PubMed ID: 30623616
[TBL] [Abstract][Full Text] [Related]
19. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients.
Hu Y; Wang LS; Jin YP; Du SS; Du YK; He X; Weng D; Zhou Y; Li QH; Shen L; Zhang F; Su YL; Sun XL; Ding JJ; Zhang WH; Cai HR; Dai HP; Dai JH; Li HP
Clin Respir J; 2017 May; 11(3):337-345. PubMed ID: 26077281
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology.
Takamura A; Hirata S; Nagasawa H; Kameda H; Seto Y; Atsumi T; Dohi M; Koike T; Miyasaka N; Harigai M
Mod Rheumatol; 2013 Mar; 23(2):297-303. PubMed ID: 22572888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
